You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Merck
Johnson and Johnson
McKinsey
Baxter

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,871,779

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,871,779 protect, and when does it expire?

Patent 8,871,779 protects OPANA ER and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 8,871,779
Title:Process for preparing morphinan-6-one products with low levels of .alpha.,.beta.-unsaturated ketone compounds
Abstract: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of .alpha.,.beta.-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. (A) ##STR00001##
Inventor(s): Buehler; Henry J. (St. Louis, MO), Dummitt; William E. (St. Louis, MO), Mannino; Anthony (Maryland Heights, MO), Aubuchon; Dennis C. (Arnold, MO), Gu; Hong (Oak Park, CA)
Assignee: Mallinckrodt LLC (Hazelwood, MO)
Application Number:11/915,606
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,871,779
Patent Claim Types:
see list of patent claims
Compound; Formulation;

Drugs Protected by US Patent 8,871,779

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-001 Dec 9, 2011 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-002 Dec 9, 2011 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-003 Dec 9, 2011 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,871,779

PCT Information
PCT FiledMarch 02, 2007PCT Application Number:PCT/US2007/005256
PCT Publication Date:September 13, 2007PCT Publication Number: WO2007/103105

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKinsey
Harvard Business School
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.